A Phase I/II, multi-center, open-label study of DYP688 in patients with metastatic uveal melanoma (MUM) and other GNAQ/11 mutant melanomas
Study of DYP688 in Patients with Melanoma
Sponsor: Novartis
Enrolling: Male and Female Patients
IRB Number: AAAU2610
U.S. Govt. ID: NCT05415072
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to identify the safest and most tolerable dose of the study drug, DYP688 that can be given to patients. Also to evaluate how well DYP688 might work in treating certain types of cancer including metastatic uveal melanoma and other melanomas with GNAQ/11 mutations (or genetic changes to the gene GNAQ/11). Metastatic means the disease has spread from an initial or primary site to different areas of the body. DYP688 is a study treatment that has not been approved by the FDA. This study is the first time the study drug is being tested in humans.
Investigator
Richard Carvajal, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Have you been diagnosed with melanoma? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162